Expertise

Scot Buchanan

Senior Vice President of Channel and Trade Strategy

Expertise:

Commercialization, Global Channel Management & 3PL, Specialty & Direct-to-Patient Distribution

Scot Buchanan, Senior Vice President of Channel and Trade Strategy at EVERSANA, brings more than 30 years of life science experience in the pharma, biotech and healthcare industries to the channel management team.

Through his previous leadership experience at Merck, AstraZeneca, CVS Specialty, AmerisourceBergen and Therigy, Scot has firsthand insight of market needs from a manufacturer and service provider perspective. His extensive experience in distribution and specialty services spans across specialty pharmacy, specialty-at-retail, buy-and-bill and health system pharmacy models. Scot’s practiced expertise in product planning, product launch, reimbursement and data reporting has launched his career into senior VP roles in pharma more than once.

At EVERSANA, Scot’s experience at leading pharma companies and drug manufacturers is leveraged to implement customized distribution strategy for clients. His expertise in specialty pharmacy needs allows him to successfully lead EVERSANA’s client account team and serve as the subject matter expert on all channel management strategies.

Scot holds a bachelor’s degree from Baylor University.

Expertise:

Pharma 3PL Services, Financial Services, Supply Chain Services, Trade Relation Support Services

Articles by Scot Buchanan

Alternative Product Distribution Model: Where Agility Meets Profitability

Distributing innovative, life-altering therapies to patients is no small feat, and manufacturers shouldn’t settle for the status quo of an outdated, one-size-fits-all model. As you develop your channel strategy, consider how your distribution model can benefit from: Read the article by EVERSANA’s Scot Buchanan, SVP of Channel and Trade Strategy to learn the three key […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.